Rankings
▼
Calendar
RIGL
Rigel Pharmaceuticals, Inc.
$541M
Q1 2021 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$81M
+45.3% YoY
Gross Profit
$81M
99.6% margin
Operating Income
$42M
51.5% margin
Net Income
$40M
48.8% margin
EPS (Diluted)
$2.20
QoQ Revenue Growth
+339.1%
Cash Flow
Operating Cash Flow
-$20M
Free Cash Flow
-$20M
Stock-Based Comp.
$3M
Balance Sheet
Total Assets
$216M
Total Liabilities
$138M
Stockholders' Equity
$78M
Cash & Equivalents
$20M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$81M
$56M
+45.3%
Gross Profit
$81M
$56M
+45.1%
Operating Income
$42M
$21M
+98.6%
Net Income
$40M
$21M
+85.9%
Revenue Segments
Contract Revenues From Collaborations
$66M
41%
License
$65M
41%
Gross Product
$16M
10%
Product
$12M
8%
Government Contract
$3M
2%
Research And Development Services And Others
$1M
1%
Discounts And Allowances
-$4M
-2%
← FY 2021
All Quarters
Q2 2021 →
RIGL Q1 2021 Earnings — Rigel Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena